CMS requires the prescribing healthcare provider to submit prior authorization confirming that the beneficiary meets the demonstrations eligibility requirements before the medication can be dispensed
Clin Toxicol (Phila) 2009;47:10111 Carnitine in the treatment of valproic acid-induced toxicity [92] Silva MF, Aires CC, Luis PB, Ruiter JP, et al
Per Omzo's published Terms and Conditions, products and services are available only within the 50 United States
19 Yet, while asymptomatic, chronically elevated aminotransferases may be of concern to healthcare providers, leading to further costly diagnostic studies or changes/restrictions in necessary medications
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming